Research strategies & Pipelines
Translational geroscience approaches to identify evolutionarily conserved aging targets and small molecule gerotherapeutics
Preclinical drug discovery in C. elegans
Our three part strategy to identify gerotherapeutics that extend healthy lifespan and delay age-related disease
Normative aging
Small molecules and natural products are tested for improved survival and health in standard lab worm models
Disease mutants
Therapeutics are screened in age-associated and rare disease mutants to identify FDA-regulated clinical applications
Drug synergy
Novel interventions are combined with known lifespan-extending compounds to create breakthrough healthy aging therapeutics
Translational drug development
From worms to mammals to clinical trials
On the path to FDA regulatory approval, therapeutics identified in worms are validated in cell culture and small mammal models with the help of our academic partners. Based on the indication and clinical endpoints pursued, clinical trials will be performed in humans or in companion animals. We are paying close attention to the Dog Aging Project TRIAD trial and will design our trials based on insights from this study.
Meet the WormBot!
Learn about the WormBot-AI, our high-throughput robotics platform combined with neural net AI to perform high-throughput health and survival analysis in worms.
‘Ora’ is translated as healthy, alive in Pascuan, the language spoken by the people of Rapa Nui, or Easter Island. This island is known to biologists of aging as the home of rapamycin, a compound with remarkable anti-aging properties in laboratory model systems and currently in clinical trials to become the first broad use gerotherapeutic.
Ora Biomedical, Inc. seeks to realize the full potential of healthy aging therapeutics by developing a new generation of broad use small molecule healthy aging interventions for humans, companion pets, and all other organisms for which prolonged healthy survival is desired. Information on this website pertains to preclinical or clinical candidates in development and has not been reviewed or approved by the Food and Drug Administration.